PMC:7105881 / 48002-48245
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1532 | 150-163 | Disease | denotes | CoV infection | MESH:D018352 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T251 | 154-163 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32265848-25640653-36511199 | 197-201 | 25640653 | denotes | 2016 |
32265848-27795425-36511200 | 215-219 | 27795425 | denotes | 2017 |
32265848-28277821-36511201 | 237-241 | 28277821 | denotes | 2017 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T268 | 0-243 | Sentence | denotes | In general, these subunit vaccines have strong immunogenicity and are capable of inducing high neutralizing antibodies and/or protection against MERS-CoV infection (Ma et al., 2014b; Zhang et al., 2016; Tai et al., 2017; Wang Y. et al., 2017). |
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T760 | 47-61 | BV_15 | denotes | immunogenicity |
T761 | 108-118 | GO:0042571 | denotes | antibodies |
T762 | 145-153 | SP_9 | denotes | MERS-CoV |
T4614 | 47-61 | BV_15 | denotes | immunogenicity |
T22946 | 108-118 | GO:0042571 | denotes | antibodies |
T84916 | 145-153 | SP_9 | denotes | MERS-CoV |